We are live on
!
Find out more
KCA
KVP Capital Advisors Portfolio holdings
AUM
$136M
This Fund
S&P 500
This Quarter
Est. Return
+25.27%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$2.34M
(+1.7%)
Cap. Flow
-$18.6M
Cap. Flow
% of AUM
-13.67%
Top 10 Holdings %
Top 10 Hldgs %
57.41%
Holding
38
New
6
Increased
2
Reduced
2
Closed
3
Avg Time Held
1.4
quarters
Top 10 Avg Time Held
1.1
quarters
Top 20 Avg Time Held
1.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tandem Diabetes Care
TNDM
|
+$5.26M |
| 2 |
ArriVent BioPharma
AVBP
|
+$3.01M |
| 3 |
Mineralys Therapeutics
MLYS
|
+$2.31M |
| 4 |
Design Therapeutics
DSGN
|
+$2.31M |
| 5 |
Artiva Biotherapeutics
ARTV
|
+$1.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$23.2M |
| 2 |
Axsome Therapeutics
AXSM
|
+$5.25M |
| 3 |
Revolution Medicines
RVMD
|
+$3.91M |
| 4 |
Travere Therapeutics
TVTX
|
+$2.31M |
| 5 |
Soleno Therapeutics
SLNO
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Travere Therapeutics
TVTX
$4.9B
| $2.22M | 1.63% |
39,000
-52,000
| -57% | -$2.31M |
2025 Q4
2 quarters
|
|
27
Zura Bio
ZURA
$383M
| $2.2M | 1.62% |
373,128
| – | – |
2026 Q1
1 quarter
|
|
|
28
Artiva Biotherapeutics
ARTV
$331M
| $1.94M | 1.42% |
+200,000
| New | +$1.82M |
2026 Q2
0 quarters
|
|
29
Nektar Therapeutics
NKTR
$1.36B
| $1.88M | 1.38% |
26,900
| – | – |
2025 Q4
2 quarters
|
|
30
Compass Therapeutics
CMPX
$169M
| $1.69M | 1.24% |
771,000
+271,000
| +54% | +$800K |
2026 Q1
1 quarter
|
|
31
Cabaletta Bio
CABA
$303M
| $1.57M | 1.15% |
505,431
| – | – |
2025 Q4
2 quarters
|
|
32
Vera Therapeutics
VERA
$2B
| $1.4M | 1.03% |
32,700
| – | – |
2025 Q4
2 quarters
|
|
33
Evolus
EOLS
$512M
| $1.04M | 0.76% |
+150,000
| New | +$886K |
2026 Q2
0 quarters
|
|
34
Celcuity
CELC
$3.22B
| $418K | 0.31% |
4,000
| – | – |
2025 Q4
2 quarters
|
|
|
YARW
35
Yarrow Bioscience
YARW
$167M
| $326K | 0.24% |
10,011
| – | – |
2025 Q4
2 quarters
|
|
|
36
Revolution Medicines
RVMD
$41.6B
| – | – |
-40,200
| Closed | -$3.91M | – |
|
|
37
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-59,700
| Closed | -$2M | – |
|
|
38
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-440,000
| Closed | -$23.2M | – |
|
Similar funds
RC
TH
WFA
SB
II
FEM
SCM
VSCP
KVP Capital Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, KVP Capital Advisors held 38 positions worth $136M, up 1.7% from $134M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
KVP Capital Advisors withdrew a net $18.6M in Q2 2026, closing 3 positions and reducing 2 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $23.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, KVP Capital Advisors opened a new position in Tandem Diabetes Care worth $4.54M.
- KVP Capital Advisors's largest Q2 2026 buy was Tandem Diabetes Care: 301,000 shares worth $4.54M.
- KVP Capital Advisors added most to Erasca in Q2 2026, an estimated $1.64M increase.
- KVP Capital Advisors's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $5.25M.
- KVP Capital Advisors fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $23.2M.
- KVP Capital Advisors's ten largest holdings make up 57% of its $136M portfolio in Q2 2026.
- KVP Capital Advisors opened 6 new positions and closed 3 in Q2 2026.
- KVP Capital Advisors's portfolio value rose 1.7% quarter-over-quarter to $136M.
Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.